Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02346253 · ClinicalTrials.gov registry record · NA
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
A NA study of Prostate Adenocarcinoma and Stage I Prostate Cancer, sponsored by Stanford University.
- Active
- Registry status
- NA
- Development phase
- 146
- Enrollment target
- 1
- Study location
NCT02346253 is a NA study of Prostate Adenocarcinoma and Stage I Prostate Cancer that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 146 participants, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02346253, a NA study of Prostate Adenocarcinoma and Stage I Prostate Cancer, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 146 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body. Brachytherapy is a type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor and may be a better treatment in patients with prostate cancer.
Conditions Studied
Interventions
- DRUG Bicalutamide
- DRUG Goserelin Acetate
- DRUG Leuprolide Acetate
- DRUG Triptorelin Pamoate
- RADIATION Internal Radiation Therapy
Study Locations (1)
California
- Stanford University, School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2015-01-13 |
| Est. Completion | 2026-05-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02346253
The ClinicalTrials.gov registry entry for NCT02346253 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (33% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Bicalutamide is the first listed.
NCT02346253 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02346253 about?
NCT02346253 is a clinical study titled "High-Dose Brachytherapy in Treating Patients With Prostate Cancer". This trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body. Brachytherapy is a type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed ...
What is the current status of trial NCT02346253?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 146 participants. The study started on 2015-01-13. Estimated completion is 2026-05-17.
What conditions does trial NCT02346253 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage III Prostate Cancer, Stage IIB Prostate Cancer, Stage IIA Prostate Cancer.
What interventions are being tested in trial NCT02346253?
The interventions under investigation include: Bicalutamide (DRUG), Goserelin Acetate (DRUG), Leuprolide Acetate (DRUG), Triptorelin Pamoate (DRUG), Internal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02346253?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02346253 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
RECRUITING · NA
-
The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
RECRUITING · NA
-
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
RECRUITING · NA
-
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
RECRUITING · NA
-
Two-fraction HDR Monotherapy for Localized Prostate Cancer
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.